Table 1
Reported regions of genomic loss in neuroblastoma tumours
| Region | Frequency of segment loss in CGH studies 101 103 104 107 | Frequency of LOH in molecular studies | Comments |
|---|---|---|---|
| CGH, comparative genomic hybridisation; LOH, loss of heterozygosity; SRO, smallest region of overlap. | |||
| 2q | 0–6% | 32%130 | SRO in 2q33 includes locus of caspase 8 gene |
| 3p | 21–32% | 10–15%131132 | Outcome difference between LOH over whole chromosome 3 (favourable) and LOH restricted to 3p (unfavourable).131 SRO 3p25.3–p14.3 |
| 4p | 15–33% | 12–20%132133 | No correlation with 1p or MYCN status133 |
| 9p | 6–21% | 17–36%132134 | Associated with advanced stage and poor outcome132 Evidence for two regions of deletion in 9p21 Associated with 1p LOH but no correlation with age or stage134 |
| 11q | 11–44% | 19–41%132,135–137 | SRO in 11q23.3. Inverse correlation with MYCN amplification. Marker of poor prognosis in MYCN non-amplified cases136,137 |
| 14q | 8–48% | 16–50%132135138–142 | No effect on prognosis. 14q LOH associated with normal 1p and MYCN.141 No correlation with clinical features142 |
| 16p | 0–6% | 9–24%132143144 | Involves hereditary neuroblastoma predisposition gene (HNB1)144 |
| 18q | 0–16% | 21%145 | No correlation with clinicopathological features |
